Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Bevacizumab in Advanced Non-Clear Cell RCC
NCT01399918Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2011
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival Rate at 6 Months. Started Jul 2011; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01399918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399918.